{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T21:43:34Z","timestamp":1774129414970,"version":"3.50.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Non-ergot dopamine agonists (NEDAs) have been used as monotherapy or as an adjunctive therapy to levodopa for many years. Novel long-acting formulations of NEDAs including pramipexole extended-release (ER), ropinirole prolonged-release (PR), and rotigotine transdermal patch have been developed. However, there is no strong evidence that a given NEDA is more potent than another. We performed a systematic review and network meta-analysis to evaluate the efficacy, tolerability and safety of six commonly used NEDAs in early Parkinson's disease (PD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Six NEDAs including piribedil, rotigotine transdermal patch, pramipexole immediate-release (IR)\/ER, and ropinirole IR\/PR were investigated. The efficacy outcomes including Unified Parkinson's Disease Rating Scale activities in daily life (UPDRS-II), motor function (UPDRS-III), and their subtotal (UPDRS-II + III), tolerability and safety outcomes were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 20 RCTs (5,355 patients) were included in the current study. The result indicated that compared with placebo, all six investigated drugs had statistically significant differences in the improvement of UPDRS-II, UPDRS-III, and UPDRS-II + III (except ropinirole PR in UPDRS-II). There were no statistically significant differences between six NEDAs for the UPDRS-II and UPDRS-III. For UPDRS-II + III, the improvement of ropinirole IR\/PR and piribedil were higher than that of rotigotine transdermal patch, and piribedil was higher than that of pramipexole IR. The surface under the cumulative ranking curve (SUCRA) indicated that piribedil resulted in best improvement in UPDRS-II and UPDRS-III (0.717 and 0.861, respectively). For UPDRS-II + III, piribedil and ropinirole PR exhibited similar improvement and both had high rates (0.858 and 0.878, respectively). Furthermore, piribedil performed better as monotherapy, ranking first in the improvement of UPDRS-II, III, and II + III (0.922, 0.960, and 0.941, separately). With regard to tolerability, there was a significant increase in overall withdrawals with pramipexole ER (0.937). In addition, the incidence of adverse reaction of ropinirole IR was relatively high (nausea: 0.678; somnolence: 0.752; dizziness: 0.758; fatigue: 0.890).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this systematic review and network meta-analysis of six NEDAs, piribedil exhibited better efficacy, especially as monotherapy, and ropinirole IR was associated with a higher incidence of adverse events in patients with early PD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1183823","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T05:28:11Z","timestamp":1686893291000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson's disease: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Xiang-Ting","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Yuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.neuron.2019.03.004","article-title":"Circuit mechanisms of Parkinson's disease","volume":"101","author":"McGregor","year":"2019","journal-title":"Neuron."},{"key":"B2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"Lau","year":"2006","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/j.parkreldis.2015.09.048","article-title":"Biomarkers in Parkinson's disease: advances and strategies","volume":"22","author":"Delenclos","year":"2016","journal-title":"Parkinsonism Relat Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov Disord"},{"key":"B5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40263-015-0293-4","article-title":"Risks of cardiac valve regurgitation and heart failure associated with ergot- and non-ergot-derived dopamine agonist use in patients with Parkinson's disease: a systematic review of observational studies","volume":"29","author":"Tran","year":"2015","journal-title":"CNS Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40265-019-01098-w","article-title":"Contemporary options for the management of motor complications in Parkinson's disease: updated clinical review","volume":"79","author":"Cabreira","year":"2019","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00702-020-02168-0","article-title":"Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson's disease patients: an European multicentre survey","volume":"127","author":"Rizos","year":"2020","journal-title":"J Neural Transm"},{"key":"B8","doi-asserted-by":"publisher","first-page":"45865","DOI":"10.1038\/srep45865","article-title":"Comparison for efficacy and tolerability among ten drugs for treatment of Parkinson's disease: a network meta-analysis","volume":"8","author":"Zhuo","year":"2017","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/WNF.0000000000000400","article-title":"The efficacy and safety of piribedil relative to pramipexole for the treatment of early Parkinson disease: a systematic literature review and network meta-analysis","volume":"43","author":"Chen","year":"2020","journal-title":"Clin Neuropharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000486252","article-title":"Comparison of the efficacy of different drugs on non-motor symptoms of Parkinson's disease: a network meta-analysis","volume":"45","author":"Li","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00228-020-02961-6","article-title":"Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis","volume":"76","author":"Binde","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2147\/NDT.S60061","article-title":"Nonergot dopamine-receptor agonists for treating Parkinson's disease - a network meta-analysis","volume":"10","author":"Thorlund","year":"2014","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B13","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/ene.15635","article-title":"Efficacy and safety of non-ergot dopamine-receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: a network meta-analysis","volume":"30","author":"Chen","year":"2022","journal-title":"Eur J Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"B15","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1002\/sim.2423","article-title":"Meta-analysis of heterogeneously reported trials assessing change from baseline","volume":"24","author":"Abrams","year":"2005","journal-title":"Stat Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: heterogeneity\u2013subgroups, meta-regression, bias, and bias-adjustment","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making."},{"key":"B19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1001\/jama.278.2.125","article-title":"Safety and efficacy of pramipexole in early Parkinson disease","volume":"278","author":"Kieburtz","year":"1997"},{"key":"B20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1212\/WNL.49.2.393","article-title":"Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group","volume":"49","author":"Adler","year":"1997","journal-title":"Neurology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1212\/WNL.49.3.724","article-title":"Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group.","volume":"49","author":"Shannon","year":"1997","journal-title":"Neurology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1001\/archneur.55.9.1211","article-title":"Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group","volume":"55","author":"Sethi","year":"1998","journal-title":"Arch Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/archneur.60.12.1721","article-title":"A controlled trial of rotigotine monotherapy in early Parkinson's disease","volume":"60","author":"Blindauer","year":"2003","journal-title":"Arch Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/mds.10359","article-title":"Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study","volume":"18","author":"Ziegler","year":"2003","journal-title":"Mov Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1002\/mds.21122","article-title":"Early piribedil monotherapy of Parkinson's disease: a planned seven-month report of the REGAIN study","volume":"21","author":"Rascol","year":"2006","journal-title":"Mov Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00415-006-0320-z","article-title":"End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease","volume":"253","author":"Thomas","year":"2006","journal-title":"J Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1002\/mds.21741","article-title":"Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole","volume":"22","author":"Giladi","year":"2007","journal-title":"Mov Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/archneur.64.5.676","article-title":"Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease","volume":"64","author":"Jankovic","year":"2007","journal-title":"Arch Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/mds.21361","article-title":"A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease","volume":"22","author":"Singer","year":"2007","journal-title":"Mov Disord."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1185\/03007990802387130","article-title":"Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study","volume":"24","author":"Stocchi","year":"2008","journal-title":"Curr Med Res Opin."},{"key":"B31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1002\/mds.23317","article-title":"Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease","volume":"25","author":"Hauser","year":"2010","journal-title":"Mov Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1002\/mds.23262","article-title":"Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease","volume":"25","author":"Rascol","year":"2010","journal-title":"Mov Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/mds.23396","article-title":"Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial","volume":"26","author":"Kieburtz","year":"2011","journal-title":"Mov Disord."},{"key":"B35","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1212\/WNL.0b013e31822affb0","article-title":"Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial","volume":"77","author":"Poewe","year":"2011","journal-title":"Neurology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/mds.23590","article-title":"Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials","volume":"26","author":"Sampaio","year":"2011","journal-title":"Mov Disord."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/mds.25537","article-title":"Transdermal rotigotine in early stage Parkinson's disease: a randomized, double-blind, placebo-controlled trial","volume":"28","author":"Mizuno","year":"2013","journal-title":"Mov Disord."},{"key":"B38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.parkreldis.2016.04.022","article-title":"Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: a randomized, double-blind, placebo-controlled pivotal study","volume":"28","author":"Zhang","year":"2016","journal-title":"Parkinsonism Relat Disord."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e27653","DOI":"10.1097\/MD.0000000000027653","article-title":"The effect and safety of ropinirole in the treatment of Parkinson disease: a systematic review and meta-analysis","volume":"100","author":"Zhu","year":"2021","journal-title":"Medicine."},{"key":"B40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.18433\/J3Q35D","article-title":"Safety and efficacy of rotigotine for treating Parkinson's disease: a meta-analysis of randomised controlled trials","volume":"20","author":"Chen","year":"2017","journal-title":"J Pharm Pharm Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/cns.12727","article-title":"Adverse effects produced by different drugs used in the treatment of Parkinson's disease: a mixed treatment comparison","volume":"23","author":"Li","year":"2017","journal-title":"CNS Neurosci Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1002\/mds.28215","article-title":"Continuous dopaminergic stimulation as a treatment for Parkinson's disease: current status and future opportunities","volume":"35","author":"Olanow","year":"2020","journal-title":"Mov Disord."},{"key":"B43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.pharmthera.2010.06.002","article-title":"From the cell to the clinic: a comparative review of the partial D2\/D3receptor agonist and \u03b12-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease","volume":"128","author":"Millan","year":"2010","journal-title":"Pharmacol Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/cns.12239","article-title":"Long-acting versus standard non-ergot dopamine agonists in Parkinson's disease: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhou","year":"2014","journal-title":"CNS Neurosci Ther."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1183823\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T05:28:15Z","timestamp":1686893295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1183823\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":44,"alternative-id":["10.3389\/fneur.2023.1183823"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1183823","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"article-number":"1183823"}}